13C-Pyruvate Breath Test Pilot Study
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- University of Florida
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Effect of dichloroacetate on pyruvate dehydrogenase and 13C02 production.
Study Overview
Brief Summary
The purpose of the test is to measure an enzyme called pyruvate. Subjects will fast for 12 hours and then undergo a breath test, have blood drawn, and cells from the inside of the mouth collected over a 12 hour period. The tests will be repeated at least a week later and subjects receive a dose of dichloroacetate (DCA)
Detailed Description
Subjects will be screened with a history and physical and have baseline laboratory values drawn to assure that the subject is healthy.Subjects will fast for 12 hours before the test. The next day they will receive a dose of 25mg of pyruvate dissolved in 80ml of Crystal Light. The pyruvate used in this study will be prepared with a nonradioactive form of carbon, called a stable isotope. It poses no hazard to the subject's health. About 50 mls of blood will be drawn over a 120 minute time period from an IV catheter placed in the arm. Subjects will also be asked to exhale into a plastic tube about 12 times in 120 minutes to collect 13C carbon dioxide (13CO2). Cells from inside of the mouth will be collected by subjects swishing a tablespoon of mouth wash for one minute and then spitting it into a sterile plastic tube. At least one week following the first admission subjects will return to repeat the above procedure and receive 25mg of dichloroacetate (DCA) one hour before receiving the pyruvate. Then the same samples will be collected. Subjects have the option of doing the tests 4 times receiving the DCA on the last visit.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •healthy volunteers
- •normal history,
- •normal physical
- •normal baseline laboratory data.
Exclusion Criteria
- •Any illness
- •Chronic health condition
- •Use of street drugs
- •Taking medication
- •Abnormal labs Abnormal physical exam -
Arms & Interventions
13C-pyruvate,13C-Lactate and dichloroacetate
During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
Intervention: 13C-Pyruvate 13C-lactate and dichloroacetate (Drug)
Outcomes
Primary Outcomes
Effect of dichloroacetate on pyruvate dehydrogenase and 13C02 production.
Time Frame: Baseline to one year
Dichloroacetate is an activator of pyruvate dehydrogenase (PDH). It will be administered to the patient who will then undergo the pyruvate breath test to measure the amount of 13CO2 expressed. The activity of 13CO2 as measured by a concentration curve will reflect PDH activity.
Secondary Outcomes
- Blood Lactate levels and 13CO2 Response to DCA(Baseline to one year)
- Conversion of 13C pyruvate to 13C pyruvate(Baseline to One Year)